Cargando…

Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator

B7-H3 was the only molecule identified with prognostic potential from a recent systematic review of the prognostic value of immune checkpoints in oral cancer. We aimed to validate this finding in a multicenter international cohort. We retrospectively retrieved 323 oral tongue squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieviläinen, Meri, Wirsing, Anna Maria, Hyytiäinen, Aini, Almahmoudi, Rabeia, Rodrigues, Priscila, Bjerkli, Inger-Heidi, Åström, Pirjo, Toppila-Salmi, Sanna, Paavonen, Timo, Coletta, Ricardo D., Hadler-Olsen, Elin, Salo, Tuula, Al-Samadi, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134649/
https://www.ncbi.nlm.nih.gov/pubmed/32959211
http://dx.doi.org/10.1007/s12105-020-01222-3
_version_ 1783695210708992000
author Sieviläinen, Meri
Wirsing, Anna Maria
Hyytiäinen, Aini
Almahmoudi, Rabeia
Rodrigues, Priscila
Bjerkli, Inger-Heidi
Åström, Pirjo
Toppila-Salmi, Sanna
Paavonen, Timo
Coletta, Ricardo D.
Hadler-Olsen, Elin
Salo, Tuula
Al-Samadi, Ahmed
author_facet Sieviläinen, Meri
Wirsing, Anna Maria
Hyytiäinen, Aini
Almahmoudi, Rabeia
Rodrigues, Priscila
Bjerkli, Inger-Heidi
Åström, Pirjo
Toppila-Salmi, Sanna
Paavonen, Timo
Coletta, Ricardo D.
Hadler-Olsen, Elin
Salo, Tuula
Al-Samadi, Ahmed
author_sort Sieviläinen, Meri
collection PubMed
description B7-H3 was the only molecule identified with prognostic potential from a recent systematic review of the prognostic value of immune checkpoints in oral cancer. We aimed to validate this finding in a multicenter international cohort. We retrospectively retrieved 323 oral tongue squamous cell carcinoma (OTSCC) samples from three different countries (Brazil, Finland, and Norway) for immunostaining and scoring for B7-H3. We evaluated tumor immunogenicity by analyzing the amount of tumor-infiltrating lymphocytes and divided the tumors into immune hot and cold. To increase the reliability of the results, both digital and manual visual scoring were used. Survival curves were constructed based on the Kaplan-Meier method, and the Cox proportional hazard model was utilized for univariate and multivariate survival analysis. B7-H3 expression was not significantly associated with overall or disease-specific survival in the whole OTSCC cohort. When divided into immune hot and cold tumors, high B7-H3 expression was significantly associated with poor disease-specific and overall survival in the immune hot group, depending on the scoring method and the country of the cohort. This was achieved only in the univariate analysis. In conclusion, B7-H3 was a negative prognosticator for OTSCC patient survival in the subgroup of immune hot tumors, and was not validated as a prognosticator in the full cohort. Our findings suggest that the immune activity of the tumor should be considered when testing immune checkpoints as biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12105-020-01222-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8134649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81346492021-05-24 Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator Sieviläinen, Meri Wirsing, Anna Maria Hyytiäinen, Aini Almahmoudi, Rabeia Rodrigues, Priscila Bjerkli, Inger-Heidi Åström, Pirjo Toppila-Salmi, Sanna Paavonen, Timo Coletta, Ricardo D. Hadler-Olsen, Elin Salo, Tuula Al-Samadi, Ahmed Head Neck Pathol Original Paper B7-H3 was the only molecule identified with prognostic potential from a recent systematic review of the prognostic value of immune checkpoints in oral cancer. We aimed to validate this finding in a multicenter international cohort. We retrospectively retrieved 323 oral tongue squamous cell carcinoma (OTSCC) samples from three different countries (Brazil, Finland, and Norway) for immunostaining and scoring for B7-H3. We evaluated tumor immunogenicity by analyzing the amount of tumor-infiltrating lymphocytes and divided the tumors into immune hot and cold. To increase the reliability of the results, both digital and manual visual scoring were used. Survival curves were constructed based on the Kaplan-Meier method, and the Cox proportional hazard model was utilized for univariate and multivariate survival analysis. B7-H3 expression was not significantly associated with overall or disease-specific survival in the whole OTSCC cohort. When divided into immune hot and cold tumors, high B7-H3 expression was significantly associated with poor disease-specific and overall survival in the immune hot group, depending on the scoring method and the country of the cohort. This was achieved only in the univariate analysis. In conclusion, B7-H3 was a negative prognosticator for OTSCC patient survival in the subgroup of immune hot tumors, and was not validated as a prognosticator in the full cohort. Our findings suggest that the immune activity of the tumor should be considered when testing immune checkpoints as biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12105-020-01222-3) contains supplementary material, which is available to authorized users. Springer US 2020-09-21 /pmc/articles/PMC8134649/ /pubmed/32959211 http://dx.doi.org/10.1007/s12105-020-01222-3 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Sieviläinen, Meri
Wirsing, Anna Maria
Hyytiäinen, Aini
Almahmoudi, Rabeia
Rodrigues, Priscila
Bjerkli, Inger-Heidi
Åström, Pirjo
Toppila-Salmi, Sanna
Paavonen, Timo
Coletta, Ricardo D.
Hadler-Olsen, Elin
Salo, Tuula
Al-Samadi, Ahmed
Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title_full Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title_fullStr Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title_full_unstemmed Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title_short Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator
title_sort evaluation challenges in the validation of b7-h3 as oral tongue cancer prognosticator
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134649/
https://www.ncbi.nlm.nih.gov/pubmed/32959211
http://dx.doi.org/10.1007/s12105-020-01222-3
work_keys_str_mv AT sievilainenmeri evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT wirsingannamaria evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT hyytiainenaini evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT almahmoudirabeia evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT rodriguespriscila evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT bjerkliingerheidi evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT astrompirjo evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT toppilasalmisanna evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT paavonentimo evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT colettaricardod evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT hadlerolsenelin evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT salotuula evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator
AT alsamadiahmed evaluationchallengesinthevalidationofb7h3asoraltonguecancerprognosticator